New Limit
Delaware corporation · 13 known investors
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology. The company builds therapeutic programs that aim to engineer cell identity and reprogram cell age for human patients.
Founders & leadership
BA
Brian ArmstrongCo-founder, Board of Directors
BB
Blake ByersDirector
JK
Jacob KimmelDirector
MP
Michael PolanskyExecutive Officer
ZD
Zavain DarDirector
Investors · 13
S32✓ verifiedPalo Alto
Valor Equity Partners✓ verifiedChicago
8VCAustin · $100K – $50M
Abstract VenturesSan Francisco · $100K – $1M
age1San Francisco · $500K – $4M
Beyond CapitalLondon
Elad GilSan Francisco · $100K – $10M
Human CapitalSan Francisco · $250K – $200M
Kleiner PerkinsMenlo Park · $500K – $15M
SciFoundersSan Francisco · $1M
Section 32Palo Alto
AbstractreportedSan Francisco · $250K – $750K
Dimension CapitalreportedSan Francisco · $1M – $10M
Reported raises · per SEC filings
Form D private placements▶$129.8MraisedMay 2025 · 38 investors · BiotechnologyRule 506(b)
▶$129.8MraisedMay 2025 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian ArmstrongDirector
- Zavain DarDirector
- Jacob KimmelExecutive Officer, Director
- Blake ByersDirector
- Offering amount
- $130M
- Amount sold
- $129.8M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$72.2MraisedJan 2025 · 21 investors · BiotechnologyRule 506(b)
▶$72.2MraisedJan 2025 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Blake ByersDirector
- Brian ArmstrongDirector
- Zavain DarDirector
- Michael PolanskyExecutive Officer
- Jacob KimmelDirector
- Offering amount
- $72.2M
- Amount sold
- $72.2M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.